iBio, Inc. Common Stock (IBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $49.79M
Last updated: Nov 17, 2026 at 4:10 PM ET
iBio, Inc. Common Stock (IBIO) Statistics
iBio, Inc. Common Stock (IBIO) has a market cap of $49.79M. Its share count is up 1112.74% from a year earlier. It holds $56.40M more cash than debt, 113.26% of its market cap.
Total Valuation
| Market Cap | $49.79M |
|---|---|
| Latest price (Nov 17, 2026) | $0.75 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | June |
Valuation Ratios
Sales and book value multiples are 778.5x and 0.9x. Its year-end P/S ranged from 2.1x to 137.2x from 2016 to 2025.
| P/S Ratio | 778.5x |
|---|---|
| Forward P/S | 45.8x |
| P/B Ratio | 0.9x |
| P/TBV Ratio | 0.9x |
Price Statistics
The stock is down 35.51% over 52 weeks and trades 21.88% below its 50-day average.
| Beta (1Y) | 2.25 |
|---|---|
| 52-Week Change | -35.51% |
| 1-Month Change | -1.58% |
| 3-Month Change | -49.79% |
| 6-Month Change | -50.13% |
| 5-Year Change | -99.80% |
| 10-Year Change | -99.97% |
| Total Return (1Y) | -35.51% |
| Total Return (3Y CAGR) | -47.61% |
| Total Return (5Y CAGR) | -70.44% |
| Max Drawdown (1Y) | -76.98% |
| Max Drawdown (3Y) | -91.06% |
| Sharpe Ratio (1Y) | -0.48 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $0.96 |
| 200-Day Average | $1.61 |
| 52-Week Range | $0.68 to $3.82 |
| RSI (14 Days) | 42.0 |
| Average Volume (20 Days) | 433.77K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.85x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.85x |
|---|---|
| Quick Ratio | 7.85x |
| Debt / Equity | 0.00x |
| Interest Coverage | -663.04x |
Returns and Efficiency
Return on equity is -38.55% and return on assets is -33.34% over the last 12 months.
| Return on Equity (ROE) | -38.55% |
|---|---|
| Return on Assets (ROA) | -33.34% |
| ROA (5Y Average) | -81.53% |
| ROIC (5Y Average) | -65.28% |
Scores
IBIO has an Altman Z-Score of -1.87, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.87 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
| Operating Income | -$35.14M |
|---|---|
| Pretax Income | -$33.04M |
| Net Income | -$33.04M |
| Reported EPS (TTM) | -$0.24 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 86.48% of the $99.11M in total assets.
| Cash and Equivalents | $56.40M |
|---|---|
| Total Debt | $0 |
| Net Cash | $56.40M |
| Net Cash Per Share | $0.54 |
| Working Capital | $80.48M |
| Shareholder Equity | $85.71M |
| Book Value Per Share | $0.82 |
| Tangible Book Value | $83.89M |
| Tangible Book Per Share | $0.81 |
| Total Assets | $99.11M |
| Total Liabilities | $13.40M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $578.00K of capital spending, operating cash flow left -$23.80M of free cash flow.
| Operating Cash Flow | -$23.22M |
|---|---|
| Capital Expenditures | $578.00K |
| Free Cash Flow | -$23.80M |
| FCF Per Share | -$0.37 |
| Depreciation and Amortization | $992.00K |
Trailing 12 months through Jun 30, 2026.
Dividends and Yields
IBIO does not pay a dividend. Its free cash flow yield is -30.57%.
| FCF Yield | -30.57% |
|---|---|
| Buyback Yield | -114.71% |
| Shareholder Yield | -114.71% |
Stock Splits
The last split was a 1-for-20 reverse split on Nov 29, 2023.
| Last Split Date | Nov 29, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Analyst Forecast
Consensus estimates put revenue growth at 65.83% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +65.83% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IBIO
What is IBIO's market cap?
iBio, Inc. Common Stock has a market cap of $49.79M.
How many shares of IBIO are outstanding?
iBio, Inc. Common Stock has 104.06M shares outstanding. The count is up 1112.74% from a year earlier.
Does IBIO pay a dividend?
No. iBio, Inc. Common Stock does not pay a dividend.
How much debt does IBIO have?
iBio, Inc. Common Stock has $0 of total debt and $56.40M of cash and equivalents, a net cash position of $56.40M.
IBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors